Dermata Therapeutics released additional results and photos from its recently completed cosmetic clinical study of Tome Foundational Treatment. The company also announced it has received over 1,000 orders for the skin renewal treatment since its recent commercial launch.
Dermata Therapeutics transitioned from a prescription R&D focus to a direct-to-consumer skincare brand, launching its first Tome product in August 2026. For the nine months ended September 30, 2026, the company reported a net loss of $7.6 million on initial sales of $74,137, with cash reserves decreasing to approximately $4.8 million.
Dermata Therapeutics reported financial results for the third quarter of 2026, highlighting its transition to a revenue-generating company following the August 2025 launch of Tome Foundational Treatment. The company reported its first product revenue and noted that approximately 30% of orders were generated via subscriptions.
Term
Q3 2026
“The third quarter represents a transformational time for Dermata as we completed our transition from a development-stage pharmaceutical company to a revenue-generating commercial skincare business.”
Gerry Proehl, Dermata’s Chairman, President, and Chief Executive Officer
“With the launch of Tome Foundational Treatment on August 25, 2026, we began generating our first product revenue, marking an important step in executing our strategy to build a differentiated skincare brand around BioneedleTM, our hero ingredient, consisting of 100% freshwater sponge, which we wild harvest and minimally process into a fine, purified powder.”
Gerry Proehl, Dermata’s Chairman, President, and Chief Executive Officer